Gary Gibson, Ph.D., director of Burke's Laboratory for Mitochondrial Biology and Metabolic Dysfunction in Neurodegeneration, will make a presentation to about 5,000 scientists and physicians from all over the world at the Alzheimer’s Association International Conference (AAIC) to be held from July 14-19 in Vancouver, Canada.
The brain’s reduced ability to use glucose is an invariant feature of Alzheimer’s disease. Mitochondria are critical in the use of glucose. The poster describes modifications of mitochondria in post mortem brains from AD patients that have never been described previously. According to the studies done by Dr. Gibson and his collaborators— Hui Xu, also at Burke, and collaborators at Mt. Sinai Medical Center in New York City, as well as in London and Beijing—these modifications can explain the reduced glucose utilization in AD brains and provide a new therapeutic target.